Noninvasive System Measures Central Venous Pressure

A new safety tracking system that provides an accurate assessment of central venous pressures is also being used to determine drug efficacy and cardiovascular health and risk during clinical trials.

The SphygmoCor is a non-invasive system used to measure central pressures, otherwise only available through an invasive catheter. The technology at the basis of the system is a transfer function that calculates the pressure wave at the ascending aorta. The transfer function is a patented mathematical model of the properties of the brachial artery and provides central data through a non-invasive recording of the pressure wave at the radial artery.

Products in the system line include an aortic blood pressure (BP) waveform analysis system that gives a 10-second snapshot of the radial arterial pressure wave and derives the ascending aortic pressure wave, providing critical cardiovascular measurements including aortic augmentation index, ejection duration, and subendocardial viability ratio. A pulse wave velocity system enables the measurement of the velocity of the pressure wave along a specific arterial segment (the velocity of the pressure wave along the artery is dependent upon the stiffness of the artery). An aortic BP monitoring system provides a continuous real-time derivation of the aortic pressure wave and key cardiovascular parameters, allowing beat-to-beat monitoring of the definitive BP of the patient. The system is ideally suited for anesthesiology and intensive care environments. An additional heart rate variability system provides a simple measure of autonomic function. The system allows analysis of both time and frequency domains, and measures of sympathetic and parasympathetic activity. The SphygmoCor system is a product of AtCor Medical (West Ryde, Australia).

"New academic research, such as the CAFE and Strong Heart studies, has served to increase awareness of our technology and the importance of noninvasive central blood pressure monitoring, among the pharmaceutical, clinical, and research communities,” said Duncan Ross, AtCor Medical CEO.


Related Links:
AtCor Medical